H ip fractures are common fragility fractures and their incidence has increased as the proportion of the elderly population increases. 1, 2 There are approximately 70,000 cases annually in the United Kingdom and this fi gure will double by 2050. 3 There is now a national effort to standardize the management of patients with hip fractures, including guidelines issued by the British Orthopaedic Association 4 and the National Institute of Clinical Excellence (NICE). 3 In these published guidelines, providing for adequate analgesia for hip fracture patients is a major priority on admission to the hospital and prior to surgery. In the United Kingdom, the admitting orthopedic team has responsibility for this pain management.
The customary practice is to follow the World Health Organization analgesic ladder, originally designed 20 years ago for cancer pain management. 5 The principles of these recommendations are: nonopioid medication for mild pain; mild opioids and adjuvant medication for moderate pain; and strong opioids and other adjuvant medication for severe pain. The NICE guideline, published in June 2011, 3 included analgesia recommendations for hip fracture patients in the United Kingdom. After assessing the pain level of the patient, regular doses of paracetamol should be the fi rst agent for pain control. Opioid medications are added according to requirements of the individual patient. The use of nonsteroidal anti-infl ammatory drugs (NSAIDs) is not recommended because of their association with peptic ulcers and renal impairment. A local nerve block, such as a femoral block, may be useful in reducing analgesic medication preoperatively, 6 but this should only be provided by trained personnel. 3 Pain due to intra-and extracapsular hip fractures is usually treated with opioid medication. Paracetamol (acetaminophen in North America) has better bioavailability when given intravenously than orally and has been successfully used in the postoperative care of orthopedic patients. However, no study has evaluated its use in the preoperative trauma patient. Our unit conducted a prospective, consecutive cohort study to investigate the opioid-sparing effect of regularly administered intravenous paracetamol compared with oral paracetamol in preoperative hip fracture patients. The total opioid dose given, based on conversion to intravenous morphine, and the reported pain score were evaluated in 75 patients. There were 28 patients in the control group who were give routine oral paracetamol and oral opioids, with morphine for breakthrough pain. There were 47 patients in the study group who received only routine intravenous paracetamol, with opioids reserved for breakthrough pain. The patients in the 2 groups had similar characteristics. The mean preoperative oral paracetamol dose for the control group was 7.2 g compared with 6.3 g in the study group. There was a signifi cant reduction (P<.005) in the mean total intravenous morphine with intravenous paracetamol (6.5 mg) compared with oral paracetamol (21.8 mg). There was no difference in the mean pain score between the groups, 2.1 vs 1.8 (P=.3). Intravenous paracetamol had a signifi cant opioid-sparing effect and satisfactory pain relief in preoperative hip fracture patients.
fracture is the defi nitive analgesia, but this may be delayed due to medical comorbidities or logistic reasons. The optimal analgesic regimen in this elderly population is controversial. Opioid medication, particularly intravenous morphine, is a strong analgesic, but these may have serious adverse effects in the elderly patient. These adverse reactions include nausea, vomiting, constipation, confusion, respiratory arrest, and even death. 7 The pharmacokinetics of opioid medication in the elderly population is poorly understood. 8 Opioid metabolism and excretion are determined by both hepatic and renal function, both of which may be suboptimal in the elderly population. We have had elderly patients experience respiratory arrest after a single dose of morphine.
Oral paracetamol is a safe analgesic, but its bioavailability when given orally can be reduced by the fi rst-pass hepatic metabolism up to 40% and its gastrointestinal absorption could be slowed by concomitant opioid administration. 9 Intravenous paracetamol has been available in the United Kingdom since 2004, but, to our knowledge, has not been studied for preoperative management in trauma patients. An earlier prototype of intravenous paracetamol has proven to be an effective, safe, and opioid-sparing analgesic agent in orthopedic postoperative care 10, 11 and in other disciplines. 12, 13 A recent review in the National Electronic Library for Medicine 14 has reaffi rmed the superior effi cacy of intravenous paracetamol as an analgesic agent. In an effort to improve safety while maintaining good analgesia, our orthopedic team was advised to consider a preoperative intravenous paracetamol-based analgesic regime for patients with hip fractures.
MATERIALS AND METHODS
We performed a prospective, consecutive cohort study in 2008 at one hospital in the United Kingdom. According to the guidelines of the National Research Ethics Service, 15 this study was considered a clinical audit and did not require a Research Ethics Committee approval. As an audit proposal, this study was submitted to and approved by the local hospital authority. Data were collected prospectively on adult patients (>15 years) with an intra-or extracapsular hip fracture admitted under the care of the senior author. Polytrauma patients, patients on chronic opioids before injury, and those patients considered medically unfi t for surgery were excluded. The fi rst part of the study was to determine the opioid use in hip fracture patients based on the World Health Organization pain ladder guidelines. These patients received regular oral paracetamol (1000 mg 4 times every 6 hours) together with regular oral opioid medication. Our unit used either codeine phosphate or tramadol as regular oral opioid analgesics and intravenous morphine was reserved for breakthrough pain. To standardize opioid measurement, oral opioid doses were converted into an intravenous morphine equivalent dose. The conversion rate for oral opioids into intravenous morphine was adopted from the UK Department of Health, 16 with 1 mg of intravenous morphine considered equivalent to 2 mg of oramorph (oral morphine), 20 mg of codeine, or 10 mg of tramadol. The pain level of these patients was routinely recorded by the nursing staff on the trauma ward, using a visual analogue pain scale of 0 to 10, with 10 signifying maximal pain. The adverse effects of opioids are diffi cult to quantify but are usually dose dependent. For this study, we decided to measure the total opioid dosage used preoperatively, from time of admission to the anesthetic room and the average preoperative pain score of these patients. Patient age, gender, ASA grade, mini-mental state examination, and time to surgery for these patients were routinely recorded.
In the second cohort of this study, a new analgesic regimen was introduced to hip fracture patients under the care of the senior author, with the use of intravenous paracetamol (1000 mg every 6 hours) preoperatively on a regular basis. Oral and intravenous opioids were used only to control breakthrough pain. The same demographic data, total opioid dose used, and mean preoperative pain score were recorded. Patients in the fi rst cohort served as the control group and those in the second cohort were termed the intervention group.
Statistical analysis was performed using a 2-sample t test, assuming equal variances, to calculate any statistical significance in the observed differences between the 2 groups.
RESULTS
In the fi rst cohort or control group, there were 28 patients, 26 women and 2 men, with a mean age of 81 years (range, 50 to 97 years), and a mean mini-mental score of 6.7 (scale of 1 to 10). There were 13 extracapsular and 15 intracapsular fractures. The mode American Society of Anesthesiologists (ASA) grade was 3 (range, 2 to 5). The mean time to surgery was 2.6 days, with a mode of 1 day, and a range of 1 to 8 days. The mean total oral paracetamol dose given preoperatively was 7.2 g. The mean total intravenous morphine dose given preoperatively (including converted opioid doses) was 21.8 mg. The mean pain score preoperatively was 2.1 (scale of 1 to 10).
In the second cohort or intervention group, there were 47 patients, 33 women and 14 men, with a mean age of 79.5 years (range, 57 to 100 years), and a mean mini-mental score of 6.6 (scale of 1 to 10). There were 19 extracapsular and 28 intracapsular fractures. The mode ASA grade was 3 (range, 1 to 4). The mean time to surgery was 2.2 days, with a mode of 1 day, and a range of 0 to 6 days. A comparison of the demographics of the 2 cohorts showed no statistically signifi cant differences ( Table 1) . The mean total intravenous paracetamol dose given preoperatively was 6.3 g. The mean total intravenous morphine dose was 6.5 mg (Figure 1 ). The mean preoperative pain score was 1.8 ( Figure 2 ).
There was no signifi cant difference between the mean age of the 2 groups (P=14) and the time to surgery (P=.17) ( Table 2 ). There was no signifi cant difference between the dose of paracetamol used by the 2 groups (P=.23), although the method of administration was different. The reduction in mean morphine dose was 70% and this was statistically significant (P<.005). Opioid dose decreased as patient age increased (Table 3 ). There was no signifi cant difference in the mean pain score between the 2 groups (P=.30).
To evaluate if the higher morphine dose preoperatively in the fi rst cohort or control group was due to a longer waiting time to surgery, a recalculated morphine dose per day was performed. The mean morphine dose per day in the fi rst cohort or control group was 9.0 mg per day and 3.8 mg per day in the second cohort or intervention group, a reduction of 58% and statistically signifi cant (P<.005).
There were no complications in either group in the preoperative period.
DISCUSSION
Paracetamol is a well known analgesic and antipyretic agent that was underutilized for many decades due to concerns about a hematological side effect. 17 However, a reevaluation led to the reentry of oral paracetamol into the United Kingdom market in 1956. Considering the advantage of paracetamol compared with NSAIDs and opioid medication with respect to adverse reactions, a parenteral form was developed for cases when oral medication could not be taken. The fi rst widely used intravenous paracetamol in the United Kingdom was Perfalgan (Bristol-Myers Squibb, Uxhall, Middlesex, United Kingdom), which used hydrophilic ingredients, like mannitol and disodium phosphate, to make it soluble and a pH buffer of sodium hydroxide and disodium phosphate to control hydrolysis. 18 The obvious advantage of intravenous compared with oral paracetamol is the avoidance of fi rst-pass hepatic metabolism. In addition, the gastrointestinal absorption of paracetamol is less reliable perioperatively in fasting and stressed patients. The analgesic effect of paracetamol begins within 5 minutes of infusion, reaching its peak at 1 hour with a half life of 4 to 6 hours, according to the product information. 19, 20 One study showed that intravenous paracetamol was superior to the oral form in achieving the therapeutic level and in maintaining a higher plasma concentration in patients. 21 The major clearance of paracetamol metabolites is via renal excretion.
The plasma concentration of intravenous paracetamol was reported to be approximately 50% greater in patients older than 80 years compared with patients between 20 and 40 years. 22 The repeated use of intravenous paracetamol has also proven to be safe provided it is kept within the daily dose limit of 4000 mg. 23 The intravenous paracetamol dose should be adjusted for patients weighing less than 50 kg. 14 The major weakness of this study is that it is not a prospective randomized study. We considered this design, but decided it was technically and ethically not feasible to recruit patients in a distressed state. Following reassurance from the hospital pain team, the orthopedic team decided to proceed with a consecutive cohort study comparing oral and intravenous paracetamol in preoperative hip fracture patients. The obvious weaknesses of this type of cohort study are lack of blinding and randomization. However, there were no signifi cant differences in patient characteristics between the 2 groups. There were already several published randomized controlled trials proving the effi cacy of intravenous paracetamol as an analgesic agent, including the studies of Lahtinen et al, 24 Pettersson et al, 25 and Cattabriga et al. 13 However, these studies focused on the postoperative setting. The results of this study are supportive of these previous studies.
The opioid-sparing effect of more than 50% in the second cohort could have been infl uenced by factors other than the intravenous use of paracetamol. The opiate conversion rate utilized in this study might be criticized, but is the one described by the United Kingdom Department of Health. The percentage decrease in the intravenous morphine dose in the second cohort is signifi cant and the absolute reduction in dose is comparable to published results. This study had a reduction of an average 16 mg of intravenous morphine when 6 g of intravenous paracetamol was used rather than oral paracetamol. Cattabriga reported a reduction of 50 mg of intravenous rescue morphine use when cardiac surgery patients received 12 g intravenous paracetamol over 72 hours. 13 This study showed that opioid dose decreased as age increased, and this decrease was greater in the second cohort or intervention group who received intravenous paracetamol. One possible explanation is the standardization of the opioid regimen in the second cohort or intervention group, with a resultant, but unintentional, reduced over-prescription of opioid medication.
Our hospital continues to use intravenous paracetamol at a dose of 1000 mg in a 100 mL vial every 6 hours, and have not encountered any problem in administering the drug to elderly patients. The 100 mL solvent does not pose any fl uid management concern in our patients, because they are NPO preoperatively and intravenous fl uid supplement is part of our routine management. We did not consider this study was suitable for a cost-benefi t analysis. The main fi nding of this study was that intravenous paracetamol was a safe and effective preoperative opioidsparing analgesic for hip fracture patients. This study also demonstrated that equivalent pain management for preoperative hip fracture patients was achieved by the same dose of paracetamol in intravenous form, with a signifi cant reduction in opioid dose.
CONCLUSION
In this prospective study of 2 cohorts of patients with intra-and extracapsular hip fractures, the use of preoperative intravenous paracetamol resulted in a signifi cant reduction in the use of opioid medication compared with oral paracetamol. There was no difference in the preoperative pain scores between the 2 cohorts and no complications from the use of this medication. Abbreviation: IV, intravenous.
